SK Biopharmaceuticals said on the 26th that the innovative epilepsy drug Cenobamate (Chinese name Yifului) has officially launched in China, starting with its first prescriptions at major hub hospitals.
This comes about three months after it received new drug approval in Dec. last year from the National Medical Products Administration (NMPA) of China as a treatment for focal-onset seizures in adults.
With first prescriptions taking place simultaneously at major hospitals across China, the company said Cenobamate has entered a full-fledged commercialization phase in the country.
Cenobamate is an innovative new drug independently developed by SK Biopharmaceuticals, and its development and commercialization in China are handled by Ignis Therapeutics, a joint venture established with global investment firm 6 Dimensions Capital.
SK Biopharmaceuticals President Lee Dong-hoon said, "Starting with China, we will solidify collaboration with partners in each region to accelerate entry into the Northeast Asian markets, including Korea and Japan."
Ignis Therapeutics CEO Eileen Long said, "The first prescriptions of Cenobamate in China mark a significant milestone in our commercialization strategy and will serve as a turning point in China's epilepsy treatment, shifting the goal from 'seizure control' to 'Seizure Freedom.'"